Literature DB >> 19398087

Decreased immune responses to influenza vaccination in patients with heart failure.

Orly Vardeny1, Nancy K Sweitzer, Michelle A Detry, John M Moran, Maryl R Johnson, Mary S Hayney.   

Abstract

BACKGROUND: Heart failure (HF) patients are at risk for influenza despite widespread vaccination. Both humoral (antibody) and cytotoxic T-lymphocyte (CTL) responses are important for protection. We explored antibody- and CTL-mediated responses to the influenza vaccine in HF patients compared with healthy controls. METHODS AND
RESULTS: We studied 29 HF patients (9 ischemic, 20 nonischemic) stable on HF therapies and 17 healthy controls. Participants had phlebotomy before and after influenza vaccination. Antibody production was measured in serum by hemagglutination inhibition assay and CTL responses (via interferon [IFN]-gamma and interleukin [IL]-10 production) were measured in isolated peripheral blood mononuclear cells with enzyme-linked immunosorbent assay. CTL responses demonstrated increased IL-10 production in HF patients after vaccination (P = .002), but similar IFN-gamma responses to healthy controls. All participants demonstrated antibody seroprotection; groups had similar rates of seroconversion (P = NS). Antibody-mediated response to the newest vaccine antigen, H3N2, was reduced in HF (P = .009).
CONCLUSIONS: Patients with HF had higher vaccine induced IL-10 concentrations, suggesting a different CTL phenotype for vaccine responses. HF patients did not mount as vigorous of an antibody immune response to the newest vaccine viral strain compared with healthy individuals. These data suggest that immunologic memory may be important for vaccine protection in HF patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19398087      PMCID: PMC2696231          DOI: 10.1016/j.cardfail.2008.11.009

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  27 in total

Review 1.  beta-adrenergic receptor blockade in chronic heart failure.

Authors:  M R Bristow
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

2.  Effect of influenza immunization on CYP3A4 activity.

Authors:  M S Hayney; R J Hammes; J P Fine; J A Bianco
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

3.  Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function.

Authors:  J Phair; C A Kauffman; A Bjornson; L Adams; C Linnemann
Journal:  J Lab Clin Med       Date:  1978-11

4.  Production of interferon-gamma and interleukin-10 after inactivated hepatitis A immunization.

Authors:  Mary S Hayney; Jessica M Buck; Daniel Muller
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

5.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.

Authors:  Kristin L Nichol; James Nordin; John Mullooly; Richard Lask; Kelly Fillbrandt; Marika Iwane
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

6.  Characterization of the immune response to trivalent influenza vaccine in elderly men.

Authors:  M Levine; B L Beattie; D M McLean; D Corman
Journal:  J Am Geriatr Soc       Date:  1987-07       Impact factor: 5.562

7.  Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly.

Authors:  Yuping Deng; Yu Jing; Ann E Campbell; Stefan Gravenstein
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

8.  The association between psychosocial factors and vaccine-induced cytokine production.

Authors:  Mary S Hayney; Gayle Dienberg Love; Jessica M Buck; Carol D Ryff; Burton Singer; Daniel Muller
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

9.  Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults.

Authors:  Janet E McElhaney; John M Herre; M Louise Lawson; Sharon K Cole; Bonnie L Burke; Jonathan W Hooton
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

10.  Effect of influenza immunization on CYP3A4 activity in vivo.

Authors:  Mary S Hayney; Daniel Muller
Journal:  J Clin Pharmacol       Date:  2003-12       Impact factor: 3.126

View more
  18 in total

1.  Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Authors:  Amy Van Ermen; Matthew P Hermanson; John M Moran; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny
Journal:  Eur J Heart Fail       Date:  2013-01-04       Impact factor: 15.534

2.  Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.

Authors:  Chris P Verschoor; Alina Lelic; Robin Parsons; Carole Evelegh; Jonathan L Bramson; Jennie Johnstone; Mark B Loeb; Dawn M E Bowdish
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 3.  Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.

Authors:  Ankeet S Bhatt; Adam D DeVore; Adrian F Hernandez; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2017-02-01       Impact factor: 12.035

4.  Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression.

Authors:  Xiaodong Zhu; Charles F McTiernan; Navin Rajagopalan; Hemal Shah; David Fischer; Yoshiya Toyoda; Dustin Letts; Jonathan Bortinger; Gregory Gibson; Wenyu Xiang; Kenneth McCurry; Michael Mathier; Joseph C Glorioso; Barry London
Journal:  Hum Gene Ther       Date:  2012-07-11       Impact factor: 5.695

5.  Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study.

Authors:  Sonja Kytömaa; Sheila Hegde; Brian Claggett; Jacob A Udell; Wayne Rosamond; Jonathan Temte; Kristin Nichol; Jacqueline D Wright; Scott D Solomon; Orly Vardeny
Journal:  JAMA Cardiol       Date:  2019-04-01       Impact factor: 14.676

6.  Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.

Authors:  Hamid Mohseni; Amit Kiran; Reza Khorshidi; Kazem Rahimi
Journal:  Eur Heart J       Date:  2017-02-01       Impact factor: 29.983

7.  High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Authors:  Orly Vardeny; Jacob A Udell; Jacob Joseph; Michael E Farkouh; Adrian F Hernandez; Alison J McGeer; H Keipp Talbot; Deepak L Bhatt; Christopher P Cannon; Shaun G Goodman; Inder Anand; David L DeMets; Jon Temte; Janet Wittes; Kristin Nichol; Clyde W Yancy; J Michael Gaziano; Lawton S Cooper; KyungMann Kim; Scott D Solomon
Journal:  Am Heart J       Date:  2018-05-23       Impact factor: 4.749

8.  Lack of persistence of influenza vaccine antibody titers in patients with heart failure.

Authors:  Caroline M Albrecht; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny
Journal:  J Card Fail       Date:  2013-12-19       Impact factor: 5.712

9.  Decreased T-cell responses to influenza vaccination in patients with heart failure.

Authors:  Orly Vardeny; John J M Moran; Nancy K Sweitzer; Maryl R Johnson; Mary S Hayney
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

10.  Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

Authors:  Orly Vardeny; KyungMann Kim; Jacob A Udell; Jacob Joseph; Akshay S Desai; Michael E Farkouh; Sheila M Hegde; Adrian F Hernandez; Allison McGeer; H Keipp Talbot; Inder Anand; Deepak L Bhatt; Christopher P Cannon; David DeMets; J Michael Gaziano; Shaun G Goodman; Kristin Nichol; Matthew C Tattersall; Jonathan L Temte; Janet Wittes; Clyde Yancy; Brian Claggett; Yi Chen; Lu Mao; Thomas C Havighurst; Lawton S Cooper; Scott D Solomon
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.